



Panacea Biotec

Innovation in support of life

5th March, 2012

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400 051
Fax No.:022-26598237 / 38
NSE Symbol : PANACEABIO

Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
Fax No.:022-22721919, 3121
BSE Scrip Code: 531349

Sub: WHO delist Company's OPV from its prequalified vaccines list

Dear Sir,

Pursuant to the provisions of Clause 36 of the Listing Agreement entered with your Exchange, we wish to inform you as under:

After a site audit of the Oral Polio Vaccine (OPV) manufacturing facility at New Delhi, the Company had undertaken several measures regarding refurbishment of the facility and strengthening of QMS from September to December, 2011. WHO team visited manufacturing facility, Okhla, New Delhi from 3 January to 1 February 2012 to assess the GMP compliance and the quality management systems applied to production and control of oral polio vaccines.

In the light of the series of changes made to the facility and WHO assessment, further corrective actions need to be implemented. Thus, the Company had arrived at a voluntary decision on 7 February 2012 to withdraw its OPV from the WHO list of Pre-qualified vaccines.

WHO has recently stated that it is confirming the removal of oral polio vaccine (OPV) produced by the Company from its list of prequalified vaccines, meaning that the OPV produced by the Company will no longer be supplied through United Nations (UN) agencies. It has also stated OPV manufactured by the Company prior to the production halt in September and being supplied through UN agencies can continue to be used, as monitoring and testing of these lots confirm compliance with quality specifications.

Panacea Biotec has played a pivotal role in the Global Polio Eradication Initiative (GPEI) as well as in India registering zero case for more than 1 year.

In pursuance of the Company's continued commitment for polio eradication, the Company had launched its Injectable Inactivated Polio Vaccine (IPV) "Polprotec" in the Indian market in 2009 and has also recently launched it in another polio endemic country Nigeria.

Contd..2/-

2

Panacea Biotec Ltd.

B-1 Extn./ G-3, MCIE, Mathura Road
New Delhi - 110 044, INDIA
Phone: D.I.D. +91-11-4167 9015
PBX: +91-11-4167 9000, Fax: +91-11-4167 9075
Email: vinodgoel@panaceabiotec.com
Website: <http://www.panacea-biotec.com>



Panacea Biotec

Innovation in support of life

: 2 :

This is for your kind information and record please.

Kindly acknowledge the receipt.

Thanking you,

Yours truly,
for Panacea Biotec Ltd.

Vinod Goel
G.M. Legal & Company Secretary

c.c. Corporate Relationship Department
The Stock Exchange, Mumbai,
1st Floor, New Trading Ring, Rotundu Building
P J Towers, Dalal Street, Fort,
Mumbai – 400 001

Panacea Biotec Ltd.

B-1 Extn./ G-3, MCIE, Mathura Road
New Delhi - 110 044, INDIA
Phone: D.I.D. +91-11-4167 9015
PBX: +91-11-4167 9000, Fax: +91-11-4167 9075
Email: vinodgoel@panaceabiotec.com
Website: <http://www.panacea-biotec.com>